TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23144444

Group type: EXPERIMENTAL
Intervention: Cetuximab plus best supportive care (BSC)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 511
Study: 21608065

Group type: EXPERIMENTAL
Intervention: 3-month exercise program (training group, N = 17)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (N = 12)
Number of subjects: 29
Study: 19663099

Group type: EXPERIMENTAL
Intervention: antihyperlipidemic decoction
Number of subjects: 77

Group type: COMPARATOR
Intervention: zhinbiticose (western medicine)
Number of subjects: 77
Study: 16962526

Group type: EXPERIMENTAL
Intervention: Cavaterm thermal balloon endometrial ablation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Hysteroscopic endometrial resection
Number of subjects: 51
Study: 16085252

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg loading dose intrarectally, followed by 650 mg every 4 hours for 48 hours)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (loading dose and subsequent doses as a placebo suppository)
Number of subjects: 65
Study: 10702890

Group type: EXPERIMENTAL
Intervention: cilostazol 100 mg twice daily for 13 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo twice daily for 13 days
Number of subjects: 15
Study: 8724092

Group type: EXPERIMENTAL
Intervention: Free fat transplantation
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard operation without fat transplantation
Number of subjects: 99
Study: 1680095

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study: 7037159

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (5000 rad in five weeks, 200 rad fractions, directed to the primary tumor area and neck)
Number of subjects: 229

Group type: COMPARATOR
Intervention: No prior irradiation (control group)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 229

Group type: COMPARATOR
Intervention: No prior irradiation
Number of subjects: 229
Study: 31086941

Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV) with/without choroid plexus cauterization (CPC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt (VPS) placement
Number of subjects: 100
Study: 30466484

Group type: EXPERIMENTAL
Intervention: mHealth intervention (text messages to support smoking cessation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (national smoking cessation help line)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 27634084

Group type: EXPERIMENTAL
Intervention: Mobilisation of the thoracic spine along with conventional physiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional stretching, strengthening, and lumbar flexion exercise programme
Number of subjects: 0
Study: 24657434

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored smoking prevention intervention
Number of subjects: 897

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 897
Study: 22226430

Group type: EXPERIMENTAL
Intervention: PDT only
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Imiquimod only
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Sequential use of PDT and imiquimod
Number of subjects: 105
Study: 20731132

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2a (PegIFNalpha‐2a)
Number of subjects: 24
Study: 17875242

Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) 150-600 mg/d
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Gabapentin (GBP) 900-3600 mg/d
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Pregabalin (PGB) vs Gabapentin (GBP)
Number of subjects: 1000
Study: 16172305

Group type: EXPERIMENTAL
Intervention: Primary closure with interrupted 4‐0 nylon suture
Number of subjects: 82

Group type: COMPARATOR
Intervention: Second intention healing
Number of subjects: 82
Study: 11836333

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (E2) 1 mg orally twice daily
Number of subjects: 7
Study: 10527995

Group type: EXPERIMENTAL
Intervention: Full planar (contour) method
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Three distance method
Number of subjects: 57

Group type: COMPARATOR
Intervention: Comparison of both methods
Number of subjects: 57
Study: 7628023

Group type: EXPERIMENTAL
Intervention: Systematic i.m. morphine regimen calculated from the initial titrated dose
Number of subjects: 70

Group type: COMPARATOR
Intervention: Initial i.v. morphine dose < or = 6 mg followed by paracetamol only
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High-dose or low-dose i.m. morphine regimen
Number of subjects: 70
Study: 2035557

Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 36
Study: 31743170

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 48
Study: 26182947

Group type: EXPERIMENTAL
Intervention: Fast track (FT) intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard track (ST) control
Number of subjects: 50
Study: 26005878

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 49

Group type: COMPARATOR
Intervention: Active monitoring
Number of subjects: 49
Study: 23063945

Group type: EXPERIMENTAL
Intervention: Nefopam (0.3 mg/kg bolus at induction followed by 0.065 mg/kg/h for 48 hours)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nefopam (0.3 mg/kg bolus at end of surgery followed by 0.065 mg/kg/h for 48 hours)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 21631378

Group type: EXPERIMENTAL
Intervention: ALA with IPL at 50 J/cm²
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ALA with IPL at 40 J/cm²
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ALA with IPL at 25 J/cm²
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ALA with IPL at 20 J/cm²
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (IPL alone)
Number of subjects: 24
Study: 19178788

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (150 mg caffeine)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Decaffeinated coffee (9 mg caffeine)
Number of subjects: 77
Study: 17382697

Group type: EXPERIMENTAL
Intervention: Thiazide treatment
Number of subjects: 9
Study: 14706768

Group type: EXPERIMENTAL
Intervention: Exercise group (n=41)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 81
Study: 11837985

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (1 g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin E (300 mg daily)
Number of subjects: 0
Study: 9624885

Group type: EXPERIMENTAL
Intervention: Combined calcium and vitamin D supplementation (500 mg calcium and 700 IU vitamin D daily for 3 years)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 389
Study: 8048325

Group type: EXPERIMENTAL
Intervention: Dental services utilization by seamen
Number of subjects: 365

Group type: COMPARATOR
Intervention: Dental services utilization by control group
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Reason for last dental visit by seamen
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Location of last dental visit by seamen
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Dental treatment timeliness by seamen
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Suggestions for improving dental services by seamen
Number of subjects: 365
Study: 3292597

Group type: EXPERIMENTAL
Intervention: Cetamolol 5-10-15 mg/d (low dose)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cetamolol 15-25-50 mg/d (high dose)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cetamolol (both doses)
Number of subjects: 108
Study: 29478187

Group type: EXPERIMENTAL
Intervention: American ginseng (AG) extract 1 g/meal (3 g/day) for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28648948

Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation (PCI)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Prophylactic Cranial Irradiation plus Consolidative Radiation Therapy (PCI+cRT)
Number of subjects: 97
Study: 25281492

Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery (SCR)
Number of subjects: 975

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 975
Study: 24152483

Group type: EXPERIMENTAL
Intervention: Carer-GP consultations directed by a self-completed checklist of needs at baseline and 3 months, GP-Toolkit to assist GPs
Number of subjects: 392

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 392
Study: 20972950

Group type: EXPERIMENTAL
Intervention: Early ECT
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conservative treatment without ECT
Number of subjects: 53
Study: 18494623

Group type: EXPERIMENTAL
Intervention: NOSF matrix
Number of subjects: 117

Group type: COMPARATOR
Intervention: ORC
Number of subjects: 117
Study: 16443517

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with cyclophosphamide, cisplatin, and carmustine followed by autologous hematopoietic support
Number of subjects: 425

Group type: COMPARATOR
Intervention: No further therapy (observation arm)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Salvage high-dose chemotherapy (HDC) after partial response to AFM
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Immediate HDC after a complete response to AFM
Number of subjects: 425
Study: 14518596

Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/day plus Clodronate (CLD) 100 mg i.m. every 10 days
Number of subjects: 45
Study: 10961957

Group type: COMPARATOR
Intervention: Intracoronary radiotherapy with beta-emitting (32)P source wire, 0 Gy (control)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intracoronary radiotherapy with beta-emitting (32)P source wire, 16 Gy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intracoronary radiotherapy with beta-emitting (32)P source wire, 20 Gy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intracoronary radiotherapy with beta-emitting (32)P source wire, 24 Gy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intracoronary radiotherapy
Number of subjects: 105
Study: 8844502

Group type: EXPERIMENTAL
Intervention: Enzyme-potentiated desensitization (EPD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (buffered saline)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mixture of allergens (open clinical trial)
Number of subjects: 20
Study: 1530798

Group type: EXPERIMENTAL
Intervention: Fadrozole 1 mg/d
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fadrozole 4 mg/d
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fadrozole (both doses)
Number of subjects: 80
Study: 6383127

Group type: EXPERIMENTAL
Intervention: Buflomedil (600 mg daily)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 31254849

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 30 l/min
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 60 l/min
Number of subjects: 57
Study: 30282685

Group type: EXPERIMENTAL
Intervention: bovine lactoferrin (bLF) added to feeds (up to 250 mg/kg/day)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: No bLF supplementation
Number of subjects: 1500
Study: 25952085

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 800

Group type: COMPARATOR
Intervention: White-light colonoscopy
Number of subjects: 800
Study: 25193471

Group type: EXPERIMENTAL
Intervention: Supervised moderate-intensity exercise training (n = 13)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional care (n = 8)
Number of subjects: 34

Group type: COMPARATOR
Intervention: NAFLD patients
Number of subjects: 34
Study: 23002720

Group type: EXPERIMENTAL
Intervention: Xylose isomerase (XI)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 20503056

Group type: EXPERIMENTAL
Intervention: VH(0.21)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NB(0.157)
Number of subjects: 8

Group type: COMPARATOR
Intervention: VH(0.29)
Number of subjects: 8

Group type: COMPARATOR
Intervention: NB(0.21)
Number of subjects: 8
Study: 17987126

Group type: EXPERIMENTAL
Intervention: Flaxseed-derived lignan capsules (360 mg lignan per day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Flaxseed-derived lignan capsules
Number of subjects: 73
Study: 15220366

Group type: COMPARATOR
Intervention: Usual care patients on various statins (n=97)
Number of subjects: 1584

Group type: COMPARATOR
Intervention: Structured care patients on atorvastatin (n=783)
Number of subjects: 1584

Group type: COMPARATOR
Intervention: Untreated dyslipidaemic patients (n=704)
Number of subjects: 1584
Study: 12365090

Group type: EXPERIMENTAL
Intervention: Telmisartan (T) 40 mg once daily
Number of subjects: 441

Group type: COMPARATOR
Intervention: Perindopril (P) 4 mg once daily
Number of subjects: 441
Study: 9650623

Group type: EXPERIMENTAL
Intervention: Reward contingencies
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Response cost contingencies
Number of subjects: 63

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 63
Study: 7866482

Group type: EXPERIMENTAL
Intervention: Tetrahydroaminoacridine (THA, tacrine) treatment for 1 year
Number of subjects: 0
Study: 2527537

Group type: EXPERIMENTAL
Intervention: Cilazaprilat (2 mg intravenous infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 193178

Group type: EXPERIMENTAL
Intervention: Early mobilization after acute myocardial infarction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged bed rest
Number of subjects: 0
Study: 29869014

Group type: EXPERIMENTAL
Intervention: Minimally invasive chevron osteotomy (MIS group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Open chevron technique (OC group)
Number of subjects: 47
Study: 28363222

Group type: EXPERIMENTAL
Intervention: Myocardial Infarction (MI)
Number of subjects: 12944

Group type: COMPARATOR
Intervention: BARC type 2 bleeding
Number of subjects: 12944

Group type: COMPARATOR
Intervention: BARC type 3a bleeding
Number of subjects: 12944

Group type: COMPARATOR
Intervention: BARC type 3b bleeding
Number of subjects: 12944

Group type: COMPARATOR
Intervention: BARC type 3c bleeding
Number of subjects: 12944
Study: 26787687

Group type: EXPERIMENTAL
Intervention: Surotomycin 250 mg twice daily for 14 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Surotomycin 500 mg twice daily for 14 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Surotomycin 1000 mg twice daily for 14 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25176098

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.5 mg bevacizumab
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-intravitreal treatment (only vitreous operation and membrane peeling)
Number of subjects: 33
Study: 22135385

Group type: EXPERIMENTAL
Intervention: 80 mg/d atorvastatin
Number of subjects: 11040

Group type: COMPARATOR
Intervention: 10 mg/d atorvastatin
Number of subjects: 11040

Group type: COMPARATOR
Intervention: 20-40 mg/d simvastatin
Number of subjects: 11040
Study: 20560292

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200-2000 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 17242096

Group type: EXPERIMENTAL
Intervention: CPAP‐40 group (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PEEP‐20 group (n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PEEP‐5 group (n = 20)
Number of subjects: 60
Study: 16037723

Group type: EXPERIMENTAL
Intervention: Asthma management education program (group education once, reinforcement education three times)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no asthma management education)
Number of subjects: 61
Study: 12111030

Group type: EXPERIMENTAL
Intervention: Enhanced key-worker liaison
Number of subjects: 84

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 84
Study: 10447227

Group type: EXPERIMENTAL
Intervention: Clodronate (400 mg capsules twice a day for 2 years)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no additional therapy)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clodronate and Control
Number of subjects: 100
Study: 7499633

Group type: EXPERIMENTAL
Intervention: Questionnaire administered before physician or family nurse practitioner visit
Number of subjects: 200
Study: 2264006

Group type: EXPERIMENTAL
Intervention: Ceftizoxime 250 mg IM
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ceftizoxime 500 mg IM
Number of subjects: 175
Study: 7358205

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 58

Group type: COMPARATOR
Intervention: Xanthinol nicotinate
Number of subjects: 58
Study: 31615197

Group type: EXPERIMENTAL
Intervention: Stepping training with external feedback for lower limb support ability
Number of subjects: 36

Group type: COMPARATOR
Intervention: Stepping training without external feedback (control)
Number of subjects: 36
Study: 30764648

Group type: EXPERIMENTAL
Intervention: CBT plus medication (escitalopram)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Medication plus CBT (CBT added after antidepressant)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Combination treatment (CBT plus medication or medication plus CBT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: CBT plus medication and Medication plus CBT
Number of subjects: 112
Study: 28353407

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: bisoprolol
Number of subjects: 927
Study: 25993594

Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg/day) plus standard ADHF therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard ADHF therapy alone (Control)
Number of subjects: 100
Study: 24315312

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 22146614

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 μg kg(‐1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 17
Study: 21123574

Group type: EXPERIMENTAL
Intervention: SYN115
Number of subjects: 21
Study: 17985810

Group type: EXPERIMENTAL
Intervention: 270 mg citrus flavonoids plus 30 mg tocotrienols (S)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 140
Study: 15848148

Group type: EXPERIMENTAL
Intervention: UWSFR measured at 11:30 a.m.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: UWSFR in the very low group at 11:30 a.m.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Perception of oral dryness ratings using Visual Analog Scales.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Perception of oral wetness in low and very low UWSFR groups at 11:30 a.m.
Number of subjects: 108
Study: 12050336

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 238

Group type: COMPARATOR
Intervention: Standard stent
Number of subjects: 238
Study: 9869018

Group type: EXPERIMENTAL
Intervention: Lercanidipine 5 mg
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Lercanidipine 2.5 mg
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg (24 h ambulatory)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Lercanidipine 2.5 mg (24 h ambulatory)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo (24 h ambulatory)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Lercanidipine 5 mg (24 h ambulatory)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Smoothness index for 2.5 mg lercanidipine
Number of subjects: 243

Group type: COMPARATOR
Intervention: Smoothness index for placebo
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Smoothness index for 5 mg lercanidipine
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Smoothness index for 10 mg lercanidipine
Number of subjects: 243
Study: 7890052

Group type: EXPERIMENTAL
Intervention: Interceed
Number of subjects: 66

Group type: COMPARATOR
Intervention: Microsurgery alone (Control)
Number of subjects: 66
Study: 2223155

Group type: EXPERIMENTAL
Intervention: Bestatin treatment in invasive treatment group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bestatin treatment in non-invasive treatment group
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group in invasive treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group in non-invasive treatment
Number of subjects: 54
Study: 6932055

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amylobarbitone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 0
Study: 31919773

Group type: EXPERIMENTAL
Intervention: Aflibercept plus micropulse laser (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aflibercept monotherapy (group B)
Number of subjects: 40
Study: 30489140

Group type: EXPERIMENTAL
Intervention: Thinking Forward with peer support
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thinking Forward without peer support
Number of subjects: 30
Study: 28957699

Group type: EXPERIMENTAL
Intervention: AraC with MK-8776 (Arm A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: AraC alone (Arm B)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MK-8776
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 26348542

Group type: EXPERIMENTAL
Intervention: Camicinal (125 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23464844

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-resistant Gram-negative coliforms identified in rectal flora
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin use in the past 3 months
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: History of heart valve replacement
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Infectious complications post-biopsy
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin resistance and infectious complications
Number of subjects: 865